Chemotherapy Induced Nausea and Vomiting (CINV) - Market Insights, Epidemiology & Market Forecast to 2023 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Chemotherapy Induced Nausea and Vomiting (CINV) - Market Insights, Epidemiology and Market Forecast to 2023" drug pipelines to their offering.

Chemotherapy-induced nausea and vomiting (CINV) are both severe side effects of cancer treatment. CINV is a condition which makes a patient uncomfortable and has to be dealt properly as many patients delay their chemotherapy cycles or even refuse further treatment due to fear from future nausea and vomiting. Also, due to nausea and vomiting induced by chemotherapy, patients can't get nutrition properly and lose their energy and may become weak which may hinder the further chemotherapy cycles as patient wouldn't be physically string to bear the chemotherapy side-effects.

According to research, the global market for Chemotherapy Induced Nausea and Vomiting (CINV) is expected to grow at a CAGR of 8.32% for the forecast period 2013-2023.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house forecast model analysis by our team of industry experts.

Scope of the Report:

  • The report will help in developing business strategies by understanding the trends shaping and driving the Chemotherapy Induced Nausea and Vomiting (CINV) market.
  • Organize sales and marketing efforts by identifying the best opportunities for Chemotherapy Induced Nausea and Vomiting (CINV) in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.
  • To understand the future market competition in the 7MM market of Chemotherapy Induced Nausea and Vomiting (CINV) and Insightful review of the key market drivers and barriers.
  • To understand the regulatory scenario in major markets.
  • The report also covers the detailed historical and forecasted Chemotherapy Induced Nausea and Vomiting (CINV)market covering United States, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2023.

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/98jdln/chemotherapy

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Gastrointestinal Drugs, Gastrointestinal Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Gastrointestinal Drugs, Gastrointestinal Drugs